Drug Pricing

Exploring 5 types of intellectual property protections in pharma

April 16, 2024 - The Journal of Advanced Pharmaceutical Technology & Research defines intellectual property as “any original creation of the human intellect such as artistic, literary, technical, or scientific creation.” Intellectual property rights or protections are offered to inventors, creators, or owners of particular intellectual property for a specified period, preventing others...

Read More


More Articles

Exploring Transparency-Rx’s pharmacy benefit manager partners

by Veronica Salib

Transparency-Rx is a recently launched organization of transparent pharmacy benefit managers working towards addressing the ongoing challenges with pharmacy benefit managers (PBMs) that have hindered access to care and significantly...

Over-the-Counter Birth Control Will Be $20 Per Monthly Supply

by Veronica Salib

On March 4, 2024, Perrigo Company, the manufacturer of Opill, announced that a monthly supply of the hormonal birth control pill costs $19.99 and is now available for pre-order. The product — and...

Senate Report Exposes Big Pharma’s Profiteering at Americans’ Expense

by Alivia Kaylor

On February 6, 2024, the United States Senate's Health, Education, Labor, and Pensions (HELP) Committee published a Majority Staff Report highlighting the issue of exorbitant drug prices in the United States. It focuses on the business...

Senate Hearing Challenges Pharma CEOs on Drug Pricing

by Alivia Kaylor

In a heated Senate hearing on February 8th, the CEOs of Bristol Myers Squibb, Johnson & Johnson, and Merck faced rigorous questioning from various United States senators regarding the exorbitant...

500 Drugs from Over 140 Brands Are Expected to Cost More This Year

by Veronica Salib

Last week, just before the end of 2023, Reuters published an article breaking a story from data analyzed by 3 Axis Advisors, a healthcare research firm. The analysis evaluated anticipated drug price...

Price Transparency Healthcare Policies Reduce Out-Of-Pocket Costs

by Editorial Staff

Price transparency enables patients to shop for the most effective and inexpensive healthcare available and is vital as patient out-of-pocket healthcare costs continue to skyrocket year-over-year.   A 2021 Kalorama Information...

How New Platforms Are Saving Patients $4 Billion on Prescription Drugs

by Veronica Salib

Today, Visory Health announced that it is ranked the fourth-largest prescription discount card in the United States, based on an analysis from IQVIA. The company revealed that it has saved 3.25 million...

CMS Announces First Drugs for Medicare Price Negotiations

by Veronica Salib

Kicking off the much-awaited drug price negotiations, the United States Centers for Medicare and Medicaid Services (CMS) and the Department of Health and Human Services (HHS) — under authority...

Ozempic in the US Costs Over Five Times More Than in Other Countries

by Veronica Salib

As weight loss drugs like Ozempic, Wegovy, and Mounjaro become increasingly popular in the United States, the financial weight of these drugs poses a significant burden for the US healthcare system....

How Do Nonprofit Pharmaceutical Companies Get Funding?

by Veronica Salib

On July 28, 2023, the United States Food and Drug Administration (FDA) approved ReVive, an opioid reversal medication manufactured by Harm Reduction Therapeutics, a nonprofit pharmaceutical company. The concept of a nonprofit...

Canadian Province Restricts Ozempic Sales to United States Citizens

by Veronica Salib

On March 28, 2023, British Columbia (BC), a Canadian Province, announced it would restrict Ozempic sales to United States citizens. The release from government officials notes that US citizens crossing...

Novo Nordisk Cuts Prices of Insulin Pens and Vials by Up to 75%

by Veronica Salib

By January 2024, Novo Nordisk plans to cut the prices of insulin pens and vials by up to 75%. The company is echoing strategies reported by Eli Lilly earlier this month, attempting to widen access to...

Abbvie Faces Competitor as a New Humira Biosimilar Comes to Market

by Veronica Salib

On January 31, 2023, Amgen announced that its product AMJEVITA, a Humira biosimilar, is now available in the United States. This new availability threatens the stake that AbbVie has held for decades...

FDA Approves $3.5 Million per Dose Hemophilia B Gene Therapy

by Hayden Schmidt

Last week, the FDA’s Center for Biologics Evaluation and Research announced the approval of Hemgenix, an adeno-associated virus vector-based gene therapy for adults with hemophilia B (congenital...

Exploring Psychedelics to Treat Mental Health Issues

by Veronica Salib

In recent years, psychedelics have been explored for pain management and treatment-resistant depression. While receiving criticism from the general public, clinicians and researchers are working tirelessly to prove the safety and efficacy...

Unpacking the 340B Drug Pricing Program, Its Impact on the Pharmaceutical Industry

by Veronica Salib

The 340B Drug Pricing Program has evolved significantly since its establishment in 1992. According to an article published by the Commonwealth Fund, the 340B Program is a federal drug pricing program that allows certain hospitals, clinics,...

AMA Analysis Finds Variations in PBM Competition

by Veronica Salib

In a recent analysis written by José R. Guardado, PhD, for the AMA, he analyzed the competition against drug intermediaries, referred to as pharmacy benefit managers (PBMs). In the report,...

Novartis Is Losing Its Battle Against a Generic Drug for MS

by Hayden Schmidt

On Thursday of last week, the US Supreme Court (SCOTUS) allowed the launch of generic versions of Novartis’s Gilenya, siding with China’s HEC Pharm Co and other pharmaceutical companies...

Recent Articles